Cite
Schoeberl B, Kudla A, Masson K, et al. Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121). NPJ Syst Biol Appl. 2017;3:16034doi: 10.1038/npjsba.2016.34.
Schoeberl, B., Kudla, A., Masson, K., Kalra, A., Curley, M., Finn, G., Pace, E., Harms, B., Kim, J., Kearns, J., Fulgham, A., Burenkova, O., Grantcharova, V., Yarar, D., Paragas, V., Fitzgerald, J., Wainszelbaum, M., West, K., Mathews, S., Nering, R., Adiwijaya, B., Garcia, G., Kubasek, B., Moyo, V., Czibere, A., Nielsen, U. B., & MacBeath, G. (2017). Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121). NPJ systems biology and applications, 316034. https://doi.org/10.1038/npjsba.2016.34
Schoeberl, Birgit, et al. "Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)." NPJ systems biology and applications vol. 3 (2017): 16034. doi: https://doi.org/10.1038/npjsba.2016.34
Schoeberl B, Kudla A, Masson K, Kalra A, Curley M, Finn G, Pace E, Harms B, Kim J, Kearns J, Fulgham A, Burenkova O, Grantcharova V, Yarar D, Paragas V, Fitzgerald J, Wainszelbaum M, West K, Mathews S, Nering R, Adiwijaya B, Garcia G, Kubasek B, Moyo V, Czibere A, Nielsen UB, MacBeath G. Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121). NPJ Syst Biol Appl. 2017 Jan 05;3:16034. doi: 10.1038/npjsba.2016.34. eCollection 2017. PMID: 28725482; PMCID: PMC5516865.
Copy
Download .nbib